← Leaderboards
Paula R Clemens
Reveragen Biopharma, Inc.
$13,640,837
Attributed
$18,454,224
Total exposure
13
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,252,988 · 12
FDA$1,201,236 · 1
By mechanism
R44$6,100,837 · 1
R01$3,437,709 · 3
U24$2,843,234 · 1
P50$2,046,470 · 1
U10$2,013,679 · 1
P01$1,127,132 · 2
Top collaborators
- Lawrence R. Wechsler8 shared
- Eric P Hoffman7 shared
Most similar at Reveragen Biopharma, Inc.
Same institution · by research overlap
- Eric P Hoffman$47,884,792
- Jesse Damsker$1,130,321
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsProgramsClinical ResearchSiteChildhoodBaseParticipantInnovationResearch PersonnelMonitorEnrollmentTranslational ResearchAdultStructureLeadershipRunningNational Institute Of Neurological Disorders And StrokeClinical DataClinical CareDystrophinAgreementPre-ClinicalCommunitiesDesign
Grant awards (48)
Network of Excellence in Neuroscience Clinical Trials (University of Pittsburgh CRS)$433,710
U24 · FY2025 · NS · contact PI
Vamorolone trial in Becker muscular dystrophy$601,151
R01 · FY2024 · FD
Network of Excellence in Neuroscience Clinical Trials (University of Pittsburgh CRS)$420,699
U24 · FY2024 · NS · contact PI
Network of Excellence in Neuroscience Clinical Trials (University of Pittsburgh CRS)$433,710
U24 · FY2023 · NS · contact PI
Pilot Trial of Vamorolone for the Treatment of Becker Muscular Dystrophy$140,289
R21 · FY2023 · AR · contact PI
Network of Excellence in Neuroscience Clinical Trials (University of Pittsburgh CRS)$311,023
U24 · FY2022 · NS · contact PI
Vamorolone trial in Becker muscular dystrophy$600,085
R01 · FY2021 · FD
Network of Excellence in Neuroscience Clinical Trials (University of Pittsburgh CRS)$311,023
U24 · FY2021 · NS · contact PI
Pilot Trial of Vamorolone for the Treatment of Becker Muscular Dystrophy$130,941
R21 · FY2021 · AR · contact PI
Network of Excellence in Neuroscience Clinical Trials (University of Pittsburgh CRS)$311,023
U24 · FY2020 · NS · contact PI
Pilot Trial of Vamorolone for the Treatment of Becker Muscular Dystrophy$276,083
R21 · FY2020 · AR · contact PI
Pivotal trial of vamorolone in Duchenne muscular dystrophy$1,499,060
R44 · FY2019 · NS
Network of Excellence in Neuroscience Clinical Trials (University of Pittsburgh CRS)$311,023
U24 · FY2019 · NS · contact PI
Establishing a Cost-effective Return of Results to Parents of Boys in VISION-DMD Clinical Trials$109,999
R44 · FY2019 · NS
Pivotal trial of vamorolone in Duchenne muscular dystrophy$1,500,000
R44 · FY2018 · NS
Network of Excellence in Neuroscience Clinical Trials (University of Pittsburgh CRS)$311,023
U24 · FY2018 · NS · contact PI
Phase IIa study of VBP15 for Duchenne muscular dystrophy$1,496,525
R44 · FY2017 · NS
Network of Excellence in Neuroscience Clinical Trials (Univ of Pittsburgh CRS)$303,000
U10 · FY2017 · NS
Phase IIa study of VBP15 for Duchenne muscular dystrophy$1,495,253
R44 · FY2016 · NS
Network of Excellence in Neuroscience Clinical Trials (Univ of Pittsburgh CRS)$303,000
U10 · FY2016 · NS
Becker muscular dystrophy: A natural history study to predict efficacy of exon sk$379,985
P50 · FY2015 · AR · contact PI
Network of Excellence in Neuroscience Clinical Trials (Univ of Pittsburgh CRS)$303,000
U10 · FY2015 · NS
VBP15, an Innovative Steroid-like Intervention on DMD: VISION-DMD$300,000
U34 · FY2015 · AR · contact PI
Becker muscular dystrophy: A natural history study to predict efficacy of exon sk$390,184
P50 · FY2014 · AR · contact PI
Network of Excellence in Neuroscience Clinical Trials (Univ of Pittsburgh CRS)$303,000
U10 · FY2014 · NS
Becker muscular dystrophy: A natural history study to predict efficacy of exon sk$376,078
P50 · FY2013 · AR · contact PI
Network of Excellence in Neuroscience Clinical Trials (Univ of Pittsburgh CRS)$216,131
U10 · FY2013 · NS
Becker muscular dystrophy: A natural history study to predict efficacy of exon sk$414,795
P50 · FY2012 · AR · contact PI
Network of Excellence in Neuroscience Clinical Trials (Univ of Pittsburgh CRS)$291,818
U10 · FY2012 · NS
Becker muscular dystrophy: A natural history study to predict efficacy of exon sk$485,428
P50 · FY2011 · AR · contact PI
Network of Excellence in Neuroscience Clinical Trials (Univ of Pittsburgh CRS)$293,730
U10 · FY2011 · NS
Genetic Rescue of Dystrophic Muscle In Utero$219,858
R01 · FY2008 · AR · contact PI
Genetic Rescue of Dystrophic Muscle In Utero$225,029
R01 · FY2007 · AR · contact PI
Genetic Rescue of Dystrophic Mucle In Utero$232,433
R01 · FY2006 · AR · contact PI
Genetic Rescue of Dystrophic Mucle In Utero$238,706
R01 · FY2005 · AR
Genetic Rescue of Dystrophic Muscle In Utero$250,036
R01 · FY2004 · AR
ANALYSIS AND MODULATION OF IMMUNITY IN GENE THERAPY$279,583
R01 · FY2003 · AI
CORE--Training Program$0
U54 · FY2003 · AR
ANALYSIS AND MODULATION OF IMMUNITY IN GENE THERAPY$271,438
R01 · FY2002 · AI
CORE--MOUSE BREEDING$196,218
P01 · FY2002 · AR
LONGTERM RESCUE OF MUSCLE FUNCTION BY DYSTROPHIN DELIVERY--ADENOVIRAL VECTORS$196,218
P01 · FY2002 · AR
ANALYSIS AND MODULATION OF IMMUNITY IN GENE THERAPY$263,533
R01 · FY2001 · AI
CORE--MOUSE BREEDING$196,218
P01 · FY2001 · AR
LONGTERM RESCUE OF MUSCLE FUNCTION BY DYSTROPHIN DELIVERY--ADENOVIRAL VECTORS$196,218
P01 · FY2001 · AR
ANALYSIS AND MODULATION OF IMMUNITY IN GENE THERAPY$255,857
R01 · FY2000 · AI
CORE--MOUSE BREEDING$171,130
P01 · FY2000 · AR
LONGTERM RESCUE OF MUSCLE FUNCTION BY DYSTROPHIN DELIVERY--ADENOVIRAL VECTORS$171,130
P01 · FY2000 · AR
GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY$37,850
K08 · FY2000 · NS